Gynecology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gynecology deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of gynecology deals from 2016 to 2024.
The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of gynecology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in gynecology dealmaking.
Chapter 3 covers the financial deal terms for deals signed in the gynecology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
Chapter 4 provides a review of the top 25 most active biopharma companies in gynecology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive and detailed review of gynecology deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of gynecology deals listed by therapeutic target.
The report also includes numerous table and figures that illustrate the trends and activities in gynecology deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Gynecology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Fully revised and updated, the report provides details of gynecology deals from 2016 to 2024.
The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of gynecology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in gynecology dealmaking.
Chapter 3 covers the financial deal terms for deals signed in the gynecology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
Chapter 4 provides a review of the top 25 most active biopharma companies in gynecology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive and detailed review of gynecology deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of gynecology deals listed by therapeutic target.
The report also includes numerous table and figures that illustrate the trends and activities in gynecology deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key Benefits
Gynecology Collaboration and Licensing Deals provides the reader with the following key benefits:
- Understand deal trends since 2016
- Browse gynecology collaboration and licensing deals
- Benchmark analysis - identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, therapy focus and technology type
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Report Scope
Gynecology Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of gynecology trends and structure of deals entered into by leading biopharma companies worldwide.Gynecology Collaboration and Licensing Deals includes:
- Trends in gynecology dealmaking in the biopharma industry
- Overview of collaboration and licensing deal structure
- Directory of gynecology deal records covering pharmaceutical and biotechnology
- The leading gynecology deals by value
- Most active gynecology licensing dealmakers
In Gynecology Collaboration and Licensing Deals, the available deals are listed by:
- Company A-Z
- Headline value
- Therapeutic area
- Technology type
Gynecology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Chapter 1 - Introduction
Chapter 2 - Trends in gynecology dealmaking
Chapter 3 - Financial deal terms for gynecology partnering
Chapter 4 - Leading gynecology deals and dealmakers
Chapter 5 - Gynecology contract document directory
Chapter 6 - Gynecology dealmaking by therapeutic target
Deal directory
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 23andMe
- Aarhus University
- Abbott Laboratories
- Abbvie
- Accord Healthcare
- Acerus
- Ache
- AdaptivEndo
- Advaxis
- Adynxx
- AIMA Laboratories
- AIVF
- Allakos
- Allegheny Technologies
- Altavant Sciences
- Amag Pharmaceuticals
- American Dental Association
- Amring Pharmaceuticals
- AntibioTx
- ApolloBio
- Aptorum Group
- Ascend Therapeutics
- Asieris MediTech
- ASKA Pharmaceuticals
- Aspen Pharmacare Canada
- AstraZeneca
- Auransa
- Avion Pharmaceuticals
- Avomeen
- Bayer
- Besins Healthcare
- Bill and Melinda Gates Foundation
- Biofourmis
- BioGen Medical
- BioNano Genomics
- BioPep
- BioSyent Pharma
- BioVaxys
- Bloom Fertility
- BMV Medica
- Brigham and Women's Hospital
- California Cryobank
- Cancer Prevention and Research Institute of Texas
- Celmatix
- Chinese Academy of Sciences
- Chugai Pharmaceutical
- Cicero Diagnostics
- Co-Diagnostics
- Cocrystal Pharma
- Conceptions Reproductive Associates of Colorado
- Consortia Health
- ConTipi
- Control Flo Medical
- Coriell Life Sciences
- Cosette Pharmaceuticals
- CR Pharma
- Dare Bioscience
- Department of Defense
- Dewpoint Therapeutics
- Duke University
- Easton Pharmaceuticals
- Egalet
- Embr Labs
- Emory University
- EndoCeutics
- Enzyvant Science
- Especificos Stendhal
- Eurofins LifeCodexx
- European Board and College of Obstetrics and Gynaecology
- European Wellness Biomedical Group
- Evidation Health
- Evotec
- Evvy
- Exeltis
- Expedeon
- ExSeed
- Ferring Pharmaceuticals
- Flo Health
- Foresee Pharmaceuticals
- Fujifilm Irvine Scientific
- Fuji Pharma
- Gameto
- Gedeon Richter
- Genea Biomedx
- Genetiks
- Genome Medical
- Genomic Prediction
- German Cancer Research Center
- Gilead Sciences
- GOG Foundation
- Good Start Genetics
- Granata Bio
- Guided Therapeutics
- Gynica
- Halt Medical
- Hammock Pharmaceuticals
- Health Decisions
- Helix
- Helix BioPharma
- Highmark Health
- Hologic
- Hope Medicine
- Hyloris Pharmaceuticals
- IBSA Group
- iGenomix
- Igyxos
- Illumina
- Indegene Lifesystems
- InnerOptic Technology
- Innovative Health Diagnostics
- Inovio Pharmaceuticals
- Inserm Transfert
- INVO Bioscience
- Jiangsu Hansoh Pharmaceutical
- Jiangsu Hengrui Medicine
- Johns Hopkins University
- Joylux
- Karolinska Institute
- KinoPharma
- Knight Therapeutics
- LinKinVax
- LUCA Science
- Lumir Lab
- mAbXience
- Massachusetts General Hospital
- Mayne Pharma
- MD Anderson Cancer Center
- MDNA Life Sciences
- Medinova
- Menarini
- MenoGeniX
- Merck and Co
- Merck KGaA
- Microbix Biosystems
- MicroGenDX
- MilanaPharm
- Millendo Therapeutics
- Millicent Pharma
- Milu Labs
- Mithra Pharmaceuticals
- Morphic Therapeutic
- Mundipharma
- MyBiotics Pharma
- Mycovia Pharmaceuticals
- Myovant Sciences
- National Human Genome Research Institute
- National Institute of Child Health and Human Development
- National Institute on Aging
- National Institutes of Health
- Novan
- NuProbe
- NX Prenatal
- ObsEva
- OmniVision Technologies
- OncoNano Medicine
- One Drop
- Osel
- Osivax
- Osteolabs
- Ovation
- Oviva Therapeutics
- OvuSense
- Palatin Technologies
- PaxGenBio
- PDS Biotechnology
- Pfizer
- PharmaJet
- Pharmanest
- Phase Genomics
- Photocure ASA
- Pierre Fabre
- PolarisQB
- Predictive Technology Group
- Procare Health
- Psyche Systems
- Purna Pharmaceuticals
- Qiagen
- Radius Health
- Rebiotix
- ReproCell
- Roivant Sciences
- Royal Philips Electronics
- Scholar Rock
- Searchlight Pharma
- Selexis
- Sema4
- Shandong Yaohua Medical Instrument
- Shenghuo Medical
- Skive Hospital
- Starpharma
- Statens Serum Institute
- St George Street Capital
- Strainprint Technologies
- Sumitomo Dainippon Pharma
- Sumitovant Biopharma
- Sun Pharmaceutical
- Syneos Health
- SynteractHCR
- Systems Oncology
- Takeda Pharmaceutical
- Tessa Therapeutics
- Texas A&M University
- Theramex
- TherapeuticsMD
- Thermo Fisher Scientific
- TiumBio
- TMRW Life Sciences
- Transgene
- twoXAR
- Ulisse Biomed
- University of Antwerp
- University of Illinois
- University of Leuven
- University of Oxford
- UpScriptHealth
- Urovant Sciences
- Vaccibody
- Valeo Pharma
- Veritas
- Viatris
- VICHY Laboratoires
- Viramal
- VirtaMed
- Vitro Biopharma
- Woom
- Xbrane Bioscience
- Xisle Pharma Ventures Trust
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
